Investor Contact
For investor related questions, please email
investors@aclaristx.com

Press Releases

Press Releases

September 27, 2022
Aclaris Therapeutics Appoints Robert Doody as Vice President, Investor Relations
August 30, 2022
Aclaris Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
August 25, 2022
Aclaris Therapeutics Announces Patent License Agreement with Lilly for Alopecia Areata
August 3, 2022
Aclaris Therapeutics Reports Second Quarter 2022 Financial Results and Provides a Corporate Update
August 1, 2022
Aclaris Therapeutics Expands Leadership Team
June 27, 2022
Aclaris Therapeutics Expands Leadership Team
June 1, 2022
Aclaris Therapeutics to Participate in the Jefferies Healthcare Conference
May 16, 2022
Aclaris Therapeutics to Participate in the H.C. Wainwright Global Investment Conference
May 10, 2022
Aclaris Therapeutics Reports First Quarter 2022 Financial Results and Provides a Corporate Update
May 3, 2022
Aclaris Therapeutics to Participate in the LifeSci Partners Immunology & Inflammation Symposium
February 24, 2022
Aclaris Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides a Corporate Update
February 2, 2022
Aclaris Therapeutics to Participate in the SVB Leerink Virtual 11th Annual Global Healthcare Conference
February 1, 2022
Aclaris Therapeutics Expands Leadership Team
January 11, 2022
Aclaris Therapeutics Provides R&D Update
Load More »